Ruxolitinib After Hematopoietic Stem Cell Transplant (HSCT)
Contact
Description
This study is enrolling people who have developed lung problems (called Bronchiolitis Obliterans or BO) after hematopoietic stem cell transplant (HSCT). BO is a type of lung injury after HSCT due to graft versus host disease. While BO is uncommon after HSCT, when BO occurs it is often diagnosed late in patients, when lung injury is hard to treat and can be irreversible, leading to long-term lung disease or even death.
The purpose of this study is to find out more about a drug called ruxolitinib (the "study drug") as an early treatment for lung injury and BO after HSCT.
Eligibility and criteria
What to expect
As a participant in this research, you will:
- Take the study drug, ruxolitinib, by mouth twice a day for 24 weeks (about 6 months)
- Complete frequent clinic visits at CHOP Philadelphia
- Have research DXA scans
- Have research pulmonary tests (oscillometry and home spirometry)
- Have frequent blood tests
- Submit biological samples (including blood, stool, urine, and more) to a biorepository at Cincinnati Children's Hospital Medical Center (CCHMC, the lead research site)
- Have research genetic tests
- Complete a study medication diary
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.